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Several radiolabeled monoclonal antibodies (mAbs) have been used as 
radioimmunotherapy (RIT) agents for cancer therapy. The use of mAbs as RIT 
agents is due to their ability to carry effectors, in the form of radionuclides which 
emit alpha (α) particles, beta (β) particles, or auger electrons, and bind specifically 
to cancer expressed receptor. This paper reports the preparation of radiolabelled 
trastuzumab in form of (177Lu-DOTA)m-PAMAM G3-F(ab')2-trastuzumab, which 
will be expected as a potential RIT agent for therapy of breast cancer overexpressed 
human epidermal growth factor receptor 2 (HER2). Due to its reduced molecular 
weight, the use of F(ab')2-trastuzumab on the aforementioned RIT agent candidate 
is expected to reach its target much faster compared to the intact trastuzumab. 
Meanwhile, the role of PAMAM G3 is to increase the specific activity of the 
radiotherapeutic agent of Lu-177 due to the ability of its 32 –NH2 functional groups 
that are able to bind many DOTAs ( 31) which in turn can bind a large number             
of 177Lu. The preparation was initiated by fragmentation of trastuzumab using                    
pepsin enzyme in 0.02 M acetic acid buffer with a pH of 4.5 to produce                              
F(ab')2-trastuzumab with a purity of 95 % after purification with PD-10                  
column. The F(ab')2-trastuzumab was then reacted with succinimidyl                                
4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) to produce SMCC-
F(ab')2-trastuzumab. The next reaction was to conjugate SMCC-F(ab')2-trastuzumab 
with DOTA-PAMAM G3.0-SH, which was prepared by reaction NHS-DOTA with 
PAMAM G3.0 and followed by reacting it with 2-iminothiolane to give (DOTA)m-
PAMAM G3.0-F(ab')2-trastuzumab. Finally, the (DOTA)m-PAMAM G3.0-F(ab')2-
trastuzumab was radiolabelled with 177Lu to produce (177Lu-DOTA)m-PAMAM 
G3.0-F(ab')2-trastuzumab, resulting in a radiochemical purity of 98 % after 
purification with PD-10 column. 
 
 
© 2017 Atom Indonesia. All rights reserved 
 
 
INTRODUCTION 
 
GLOBOCAN is a project under the 
International Agency for Research on Cancer, 
World Health Organization, that estimates and 
presents information about the incidence of death, 
cancer, and its prevalence for countries and regions 
around the world. In 2012, GLOBOCAN estimated 
                                                 
 Corresponding author. 
   E-mail address: r_dini@batan.go.id 
   DOI: http://dx.doi.org/10.17146/aij.2017.623 
that there were 14.1 million new cancer cases in the 
world and 8.2 million people died from them [1]. 
The increasing occurrence of new cancer 
cases each year requires effective treatments. 
Monoclonal antibody (mAb) has long been used for 
cancer therapy; the target is a tumor antigen.                 
The mechanism of actions of antibodies in killing 
tumor cell are by inhibiting transduction signal, 
blocking the receptor, reducing proliferation, 
inducing apoptosis, using immune-mediated                   
(T-cells, antibody dependent cell mediated 
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cytotoxicity) and also by delivering conjugated 
antibody which is loaded with a toxin, radioisotope, 
or drug [2]. 
Trastuzumab was approved by FDA for 
human epidermal growth factor receptor type 2 
(HER2)-positive breast cancer in 1998. 
Trastuzumab binds selectively to the extracellular 
domain of HER2 receptor. HER2 is one of the 
members of epidermal growth factor receptor 
(EGFR) family, which consists of HER1, HER2, 
HER3, and HER4. HER2 has been developed into a 
cancer therapeutic target because its level is closely 
related with tumorigenesis. HER2 is overexpressed 
approximately 30 % in breast cancer. Also, 
overexpressions of HER2 are found in other cancers 
such as the pancreas, ovarian, and colorectal 
cancers. The result of in-vitro and in-vivo studies 
showed that trastuzumab inhibit proliferation of 
HER2-positive tumor cell [3-5].  
Radioimmunotherapy (RIT) can be used as an 
alternative cancer treatment in which a radioisotope 
is combined with a monoclonal antibody to create a 
tumor-specific targeting agent [6]. The trastuzumab 
used in this research was fragmented into a bivalent 
antibody fragment (F(ab')2) using pepsin enzyme to 
reduce molecular weight. An F(ab')2 antibody can be 
obtained by cleaving the carbonyl side of the residue 
under disulfide bond. Although F(ab')2 fragments 
have a smaller size than the corresponding intact 
antibody, the fragments reportedly do not lose the 
ability to bind to the antigens and give a better tissue 
penetration [7,8]. Following the fragmentation, 
F(ab')2 fragments were combined with bifunctional 
chelating agents (BFC) and dendrimer. Bifunctional 
chelating agents contain a reactive group for 
coupling to proteins (or other molecules) and a 
chelate for complexing to certain radioactive    
metals. Mono-N-hydroxysuccinimide ester 1,4,7, 
10-tetraazacyclododecane-N,N’,N’,N’”-tetraacetic 
acid (NHS-DOTA) is an example of bifunctional 
chelating agent [9] utilized in this research. 
Dendrimers are monodisperse, homogenous, 
nano-sized macromolecules [10] that have a large 
surface functional group [11] like a tree branching 
lot. The structure of dendrimer that includes 
molecular weight, size, and the amount of surface 
functional groups can be modified. Therefore, 
dendrimers exist in the form of low to high 
generation namely dendrimer G1 (generation 1), G2, 
G3, and so on [11]. Poly(amidoamine) G3.0 
(PAMAM G3.0) is a dendrimer that has been used 
as a drug delivery agent. It has 32 primary amine 
groups on its molecule surface. These groups can be 
used to bind both complex compounds such as 
177
Lu-DOTA, and molecular carriers such as 
trastuzumab [12]. 
This study aims at developing a new 
radioimmunotherapeutic agent of (
177
Lu-DOTA)m-
PAMAM G3-F(ab')2-trastuzumab. (DOTA)m-
PAMAM G3-F(ab')2-trastuzumab is synthesized 
through four reaction steps before being labeled 
with 
177
Lu. The synthesis steps are: first, 
conjugation of ligand to the dendrimer; second, 
activation of NHS-DOTA-PAMAM G3.0; third, 
activation of the F(ab')2-DOTA-trastuzumab with 
succinimidyl-4-(N-maleimidomethyl) cyclohexane-
1-carboxylate (SMCC); and finally, conjugation of 
PAMAM G3.0 with F(ab')2-trastuzumab-SMCC. 
The aim of this preliminary study is to synthesize 
and characterize (
177
Lu-DOTA)m-PAMAM G3-
F(ab')2-trastuzumab as a radiopharmaceutical for 
cancer therapy. 
 
 
 
EXPERIMENTAL METHODS 
 
One of the materials used in this study               
was trastuzumab/Herceptin, that was obtained              
from Roche. Another material, radionuclide                 
177
Lu, was prepared by irradiating 
176
Lu in the               
G.A. Siwabessy Multi-Purpose Reactor and                   
then processed at the Center for Radioisotope                
and Radiopharmaceutical Technology, Indonesian 
National Nuclear Energy Agency (PTRR-BATAN). 
The other materials were sulfo-NHS-                       
DOTA (Macrocyclic), PAMAM dendrimers G 3.0 
(Sigma-Aldrich), pepsin from porcine gastric 
mucosa (Sigma-Aldrich), sulfo-SMCC (Thermo 
Fisher Scientific), and Traut’s reagent of                           
2-iminothiolane (Thermo Fisher Scientific). 
Furthermore, bovine serum albumin, trizma                
base, monobasic sodium phosphate (NaH2PO4.H2O), 
dibasic sodium phosphate (Na2HPO4.2H2O),               
DMF, trizma base and tris-glycine were all 
purchased from Sigma, while EDTA, HCl, and 
NaOH were purchased from E-Merck. Further                    
materials were protein standard and                 
protein dye (Bio-Rad), dialysis cassettes 20000                
Da MWCO (Thermo Scientific), Sephadex G25 M 
resin and PD-10 (Sephadex G25 Columns,                    
GE Healthcare), and instant thin layer 
chromatography-silica gel (iTLC-SG) strips 
(Agilent). Equipment used for analaysis                     
were Gamma Counter (Nucleus), High Performance 
Liquid Chromatography (HPLC, Shimadzu) 
equipped with Size Exclusion Column                         
(SEC column, Agilent), thermomixer and 
micropipette (Eppendorf), shaker (Heidolph                 
Unimax 1010), micro spectrophotometer                    
(BioTek), roller mixer (Multimix MMI Luckham), 
and dose calibrator (Capintec).  
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Preparation of F(ab’)2-trastuzumab 
 
After dialysis process using dialysis cassette 
finished, an aliquot (100 µL) of digestion buffer was 
added to 0.75 mg pepsin. It was mixed until pepsin 
properly dissolved, followed by addition of 3 mL of 
dialyzed trastuzumab (5 mg/mL) [13]. The mixture 
was then incubated at 37 °C. An aliquout of TrisHCl 
10 mM at pH 8.0 was added into each sample to 
stop fragmentation process. Purification of F(ab’)2-
trastuzumab was carried out by using a PD-10 
desalting column. The resulting eluate was collected 
in 0.25 mL fractions which were then analyzed by 
using HPLC. The fraction of F(ab’)2-trastuzumab  
with a purity of > 95 % was then pooled for use in 
further study [7,9]. 
 
 
Synthesis of DOTA-PAMAM G 3.0-F(ab’)2-
trastuzumab 
 
Conjugation of ligand to dendrimer 
 
PAMAM G3.0 in 0.1 M phosphate buffer at 
pH 7.4 was added into sulfo-NHS-DOTA solution 
in 0.1 M phosphate buffer (mole ratio 1:96). The pH 
of the reaction was adjusted to 7.4. The mixture was 
then incubated at 4 °C for 24 hours while being 
rotated using a roller mixer. The ligand that did not 
react with the PAMAM G3.0 was separated using 
PD-10 column. All purification processes in this 
work used PD-10 column which was pre-blocked 
with BSA, equilibrated with the desired eluent, and  
then eluted with 0.01 M PBS at pH 7.4 (contains 5 
mM EDTA). The eluates from a purification step of 
(DOTA)m-PAMAM G3.0 conjugate were separated 
into 30 fractions of 0.25 mL each. Each fraction was 
taken (10 µL) and tested using protein dye 
(colorimetric assay). Fractions which gave a blue 
color indicating the presence of (DOTA)m-
PAMAM G3.0 were then pooled and used for 
further study. 
 
 
Activation of (DOTA)m-PAMAM G3.0 with 
Traut’s reagent 
 
Traut’s reagent (2-iminothiolane) was 
dissolved in 0.05 M phosphate buffer of pH 7.4 
containing 5 mM EDTA (1 mg/ mL). An aliquot of 
2-iminothiolane was added into (DOTA)m-
PAMAM G3.0 conjugate with a mole ratio of 2:1 
followed by incubation at room temperature for 1 h 
under nitrogen gas atmosphere to form (DOTA)m-
PAMAM G3.0-SH that was then purified                    
using PD-10 column in similar to that of Sec. 2.1. 
The eluates were collected and separated into 40 
fractions of 0.25 ml each. Each fraction was taken 
(10 µL) and tested using the dye-protein. Fractions, 
which gave a blue colour indicating the presence of 
(DOTA)m-PAMAM G3.0-SH, were then retrieved 
and used for further study. 
 
 
Activation of F(ab’)2-trastuzumab with SMCC 
 
Sulfo-SMCC was dissolved in a small amount 
of DMSO/DMF, and then the concentration was 
adjusted to 1 mg/mL by addition of 0.1 M PBS at 
pH 7.4 (containing 5 mM EDTA). An aliquot of the 
sulfo-SMCC was added into F(ab’)2-trastuzumab 
(mole ratio 10:1) followed by incubation at room 
temperature for 30 minutes. Purification of F(ab’)2-
trastuzumab-SMCC from byproducts was conducted 
using the PD-10 column (containing 5 mM EDTA) 
in a similar manner with Section 2.1. The eluates 
were collected and separated into 40 fractions of 
0.25 ml each . Each fraction was taken (10 µL) and 
tested using the dye- protein. Fractions which gave a 
blue color indicating the presence of F(ab’)2-
trastuzumab with SMCC were then retrieved and 
used for further study. 
 
 
Conjugation of (DOTA)m-PAMAM G3.0-SH 
with F(ab’)2-trastuzumab-SMCC 
 
The activated (DOTA)m-PAMAM G3.0-SH 
was added to the activated trastuzumab (F(ab’)2-
trastuzumab-SMCC). The mixture was incubated 
while being rotated overnight at 4 °C followed by 
dialyzing, using dialysis cassette with a molecular 
weight cutoff (MWCO) of 20 kDa, with 0.25 M 
ammonium acetate at pH 7.4 containing 1.2 g 
Chelex-100. The dialysis was carried out at 4 °C for 
72 hours with three buffer changes. 
 
 
Labeling of DOTA-PAMAM-F(ab’)2- 
trastuzumab with 177Lu 
 
Preparation of 177LuCl3 
 
The first step was to prepare a solution                
of 
177
LuCl3 by irradiating 0.3-0.4 mg of 
176
Lu2O3 
(64.30 % isotopically enriched) in the                         
G.A. Siwabessy Multi-Purpose Reactor (National 
Nuclear Energy Agency of Indonesia) for four days. 
The irradiated target was dissolved by addition of                
2 mL of 6 M HCl. The mixture was left to         
stand for 30 min after which 2 mL of H2O2                     
was added. The mixture was then heated to get               
dried and the residue was redissolved in 3 mL                   
of HCl 0.05 M.  
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Labeling process 
 
The solution of 
177
Lu was diluted with 0.25 M 
ammonium acetate at pH 7.5 (1:3), and  
subsequently added into the (DOTA)m-PAMAM 
G3.0-F(ab’)2-trastuzumab. The pH of the solution 
was  adjusted to 5.5 with 0.1 N NaOH, and then it 
was incubated for 90 min at 37 °C. An aliquot of 
0.05 M EDTA (mol ratio EDTA : 
177
Lu = 20:1) was 
added to the mixture, followed by incubation for          
5 min at 37 °C. The reaction mixture from 
radiolabeling process was loaded into a PD-10 
column. The column was then eluted using 0.01 M 
PBS at pH 7.4, and the eluent was collected and 
separated into 50 fractions (0.25 mL/fraction).          
The radioactivity of each fraction was measured 
using a dose calibrator. The fractions, which             
had high radioactivity, were then tested for              
their radiochemical purity using thin layer 
chromatography (ITLC-SG strips (1 cm×10 cm) and 
saline solution were used as a stationary and mobile 
phases, respectively [7]. The radiochemical purity of 
the (
177
Lu-DOTA) m-PAMAM-F(ab’)2-trastuzumab 
was calculated based on the ratio between the count 
rate under the (
177
Lu-DOTA)m-PAMAM-F(ab’)2-
trastuzumab peak and the total count rate.  
 
 
RESULTS AND DISCUSSION 
 
The chromatogram of standard proteins that 
have passed the SEC column is shown in Fig. 1 (a). 
This chromatogram shows the five peaks of the five 
standard proteins with different molecular weights 
as indicated by their ndiffering retention times (RT). 
Figure 1 (b) demonstrates the chromatogram of 
trastuzumab. Trastuzumab has a molecular weight 
of ~148 kDa [14]. Thus, when compared with the 
chromatogram of the standard protein, the RT of 
intact trastuzumab should be similar to the RT of            
-globulin (molecular weight of 158 kDa). The RT 
of -globulin is 11.243 minutes while the RT of the 
intact trastuzumab is 11.250 minutes for the percent 
area of 100 % (Fig. 1 (a) and 1 (b)). It is assumed 
that the data measured using the HPLC in this 
experiment agree with the reference data. 
The chromatogram of fragmented 
trastuzumab in form of F(ab’)2-trastuzumab 
followed by purification using a PD-10 column is 
shown in Fig. 1 (c). When compared with the 
standard protein, peak of F(ab’)2-trastuzumab 
should be between the second peak (-globulin,  
MW 158 kDa) and the third peak (ovalbumin,         
MW 44 kDa). The RT of F(ab’)2-trastuzumab was 
11.890 minutes with the percentage area of 95 %. 
The measured results demonstrate that the 
experimental data is in good agreement with the 
reference. There is a small peak with  a percentage 
area of 5 % in the retention time of 14.433 minutes, 
which is assumed  to be the Fc portion that has not 
been removed completely through the column. 
After obtaining high-purity trastuzumab 
fragments, the next step was to synthesize 
(DOTA)m-PAMAM G3.0-F(ab')2-trastuzumab. This 
synthesis reaction was carried out in the four stages 
as described in the previous section. The reason of 
the use of NHS-DOTA instead of p-SCN-Bn-DOTA 
for preparing the conjugates of NHS-DOTA-
PAMAM G3.0 was its low solubility of (DOTA-p-
SCN-Bn)n PAMAM G3.0 conjugate after the freeze 
dry process as evidenced in the previous studies. 
 
 
 
 
Fig. 1. Chromatograms: protein standard (a), intact trastuzumab 
with RT: 11.250 (b), and F(ab’)2-trastuzumab with RT: 11.907 
(c). Standard protein consists of thyroglobulin (670 kDa, RT: 
10.153 min), -globulin (158 kDa, RT: 11.243), ovalbumin                
(44 kDa, Rt : 12.957), myoglobulin (17 kDa, RT : 15.103), and 
Vitamin B12 peak (1.35 kDa, RT: 22.120). Column: SEC, 
Eluent: 0.01 M PBS pH 7.4, Flowrate:  0.5 ml/min. 
 
Therefore, it was impossible to reconstitute 
the conjugate completely before its labeling                    
with 
177
Lu [15]. The next step was the activation               
of dendrimer conjugate, (DOTA)m-PAMAM G3.0. 
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The activation of this conjugate with                        
2-iminothiolane was intended to provide a 
sulfhydryl group on the surface of PAMAM G 3.0 
for further coupling. The resulted (DOTA)m-
PAMAM G3.0-SH was purified from unreacted 2-
iminothiolane and other by-products using a PD-10 
column (eluted with eluent of phosphate buffer 0.05 
M at pH 7.4 containing EDTA 5 mm).  
 
 
Fig. 2. Fractions of : (a). Activated DOTA-PAMAM G-3.0-
sulfhydril; and: (b). Activated F(ab’)2-trastuzumab-SMCC. 
 
The eluates were collected and separated into 
20 fractions of 0.25 mL each. Each fraction was 
taken (10 L) and tested using the dye protein. In 
this assay, the fraction containing DOTA-PAMAM 
G3.0-SH was blue, while the fraction containing              
no (DOTA)m-PAMAM G3.0-sulfhydril was brown 
[16]. The positive fractions containing (DOTA)m-
PAMAM G3.0-SH were fractions numbered 14-18 
(Fig. 2(a)). The color changes in this colorimetric 
assay are due to the electrostatic interactions 
between the remaining primary amine groups of 
dendrimer and protonated one with one sulfo groups 
of Coomassie blue [12]. 
The subsequent step was the activation of 
F(ab')2-trastuzumab by reacting it with maleimide  
to provide F(ab')2-trastuzumab-SMCC that was                 
then coupled specifically with the sulfhydryls of 
(DOTA)m-PAMAM G3.0-SH. The purification and 
testing for F(ab’)2-trastuzumab-SMCC were carried 
out in similar manners to that of (DOTA)m-
PAMAM G3.0-sulfhydril. The positive fractions 
containing trastuzumab-SMCC were fractions 
numbered 14-19. The result of a colorimetric assay 
of F(ab’)2-trastuzumab-SMCC is shown in Fig. 2(b). 
The last step was conjugation of DOTA-PAMAM 
G3.0-SH with F(ab')2-trastuzumab-SMCC to                 
form a DOTA-PAMAM G3.0-F(ab’)2-trastuzumab 
conjugate. The reaction mixture was incubated 
overnight, which was then dialyzed using Slide-A-
Lyzer dialysis cassettes (20 kDa MWCO) with                 
0.25 M ammonium acetate at pH 7.2 containing            
1.2 grams of Chelex-100. 
The formation of the (
177
Lu-DOTA)m-
PAMAM G3.0-F(ab')2-trastuzumab complex was 
performed by reacting a DOTA-PAMAM G3.0-
F(ab’)2-trastuzumab conjugate with 
177
Lu
3+
 at               
pH 5-5.5 with incubation time of 90 minutes. At the 
end of the incubation time, EDTA was added to the 
reacting mixture to bind to the free 
177
Lu
3+
, which 
was not bound to the DOTA-PAMAM G3.0-
F(ab')2-trastuzumab [16]. The labeling percentage  
of the (
177
Lu-DOTA)m-PAMAM G3.0-F(ab')2-
trastuzumab before and after passing through                
the column was determined using thin layer 
chromatography (of ITLC-SG and saline solution as 
stasionary and mobile phases, respectively).                   
The determination of the labeling percentage before 
loading into the column is useful to determine the 
efficiency of the purification process. 
 
 
 
 
 
 
 
Fig. 3. Radiochromatograms of (177Lu-DOTA)m-PAMAM 
G3.0-F(ab’)2-trastuzumab: (a) before purification, and: (b) free 
177Lu (in the form of 177Lu –EDTA). 
Figure 3(a) is a radiochromatogram of (
177
Lu-
DOTA)m-PAMAM G3.0-F(ab')2-trastuzumab 
before passing through the PD-10 column.                     
The presence of free 
177
Lu (in the form of 
177
Lu-
EDTA) was confirmed with a radiochromatogram of 
the 
177
Lu-EDTA that was prepared separately and 
also spotted on ITLC-SG strips developed with 
saline solution (see Fig. 3(b)). It can be seen that 
there was free 
177
Lu (Rf=1) in the reaction mixture 
that contain a main product of the (
177
Lu-DOTA)m-
PAMAM G3.0-F(ab')2-trastuzumab (Rf=0) that has a 
radiochemical purity of 75.83 ± 1.33 %. 
(a) 
(b) 
(a) 
(b) 
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Fig. 4. One of the elution profiles of (177Lu-DOTA)m-PAMAM 
G3.0-F(ab’)2-trastuzumab after passing through the PD-10 
column (Eluent: 0.01 M PBS pH 7.4). 
 
The purification of (
177
Lu-DOTA)m-PAMAM 
G3.0-F(ab’)2-trastuzumab was carried out using the 
PD-10 column and its elution profile is                
shown in Fig. 4. It appears that based on the                           
177
Lu radioactivity there are two distinct                        
peaks of (
177
Lu-DOTA)m-PAMAM G3.0-F(ab')2-
trastuzumab and 
177
Lu-EDTA, respectively. 
Fractions which have high radioactivities were              
then tested for their radiochemical purity using               
the ITLC-SG.  
 
 
 
 
Fig. 5. Radiochromatogram of a fraction with the highest 
radioactivity. Stationary phase: ITLC SG,  mobile phase: saline. 
 
Figure 5 shows an ITLC-SG radiochro-
matogram of fraction with the highest radioactivity. 
The radiochemical purity of fraction as (
177
Lu-
DOTA)m-PAMAM G3.0-F(ab')2-trastuzumab in the 
ITLC-SG radiochromatogram is 98.36 ± 0.25 %. 
The impurities in form of free 
177
Lu (
177
Lu which                 
is not label to DOTA-PAMAM G3.0-F(ab')2-
trastuzumab) decrease from 24.17 % to 1.64 %. 
 
CONCLUSION 
 
The (
177
Lu-DOTA)m-PAMAM G3-F(ab')2-
trastuzumab, which is expected to be a potential RIT 
agent for therapy of breast cancer overexpressed 
HER2, has been prepared. F(ab')2-trastuzumab as a 
precursor was prepared by enzymatic digestion of 
intact trastuzumab using pepsin. The radiolabeling 
of (DOTA)m-PAMAM G3.0-F(ab')2-trastuzumab 
with 
177
Lu at 37 C and  incubation time of 90 min 
results in (
177
Lu-DOTA)m-PAMAM G3-F(ab')2-
trastuzumab with the radiochemical purity of 98.36 
± 0.25 % after purification with PD-10 column.           
The stability and other tests of (
177
Lu)n-(DOTA)m-
PAMAM G3.0-F(ab')2 will be reported shortly.  
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